Boston, Massachusetts
Cancer biologic therapy trials in Boston, MA
61 cancer biologic therapy studies are recruiting participants at sites in Boston as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Boston at a glance
- 61 studies are recruiting at a site in Boston.
- By phase: Phase 1 (11), Phase 1/2 (11), Phase 2 (16), Phase 2/3 (2), Phase 3 (18), No phase (1), Observational (2). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (36), university, hospital or other (13), government (12).
- By research area: Lymphoma (19), Breast Cancer (16), Lung Cancer (13), Melanoma (8), Prostate Cancer (3), Pancreatic Cancer (2).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Boston
Basic details from each study's public record (the 30 most recently updated of 61). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05422794 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Dana-Farber Cancer Institute · Tufts Medical Center
- Registry record
- NCT05564377 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Dana Farber Cancer Institute ( Site 0090) · Massachusetts General Hospital Cancer Center ( Site 0091)
- Registry record
- NCT06966700 · updated
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Dana-Farber Cancer Institute ( Site 0050)
- Registry record
- NCT06686394 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Tufts Medical Center
- Registry record
- NCT06058377 · updated
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT07137416 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Lung cancer studies recruiting in Boston
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Dana Farber Cancer Hospital ( Site 0155) · Massachusetts General Hospital ( Site 0136)
- Registry record
- NCT06623422 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Beth Israel Deaconess Medical Center · Boston Medical Center · Dana-Farber Cancer Institute
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Tufts Medical Center
- Registry record
- NCT06096844 · updated
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Study site
- Beth Israel Deaconess Medical Center
- Registry record
- NCT06667908 · updated
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Strand Therapeutics Inc.
- Study site
- Massachusetts General Hospital
- Registry record
- NCT07751042 · updated
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- Phase 3
- All ages
- All sexes
- Sponsor
- Pierre Fabre Medicament
- Study site
- Dana Farber Cancer Institute, Brigham and Women's Hospital (Adults and Pediatrics)
- Registry record
- NCT03394365 · updated
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
- Observational
- Ages 15 and older
- All sexes
- Sponsor
- Dana-Farber Cancer Institute
- Study sites
- Dana-Farber Cancer Institute · Massachusetts General Hospital
- Registry record
- NCT05265429 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Boston
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
- No phase
- Ages 55 to 69
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
- Registry record
- NCT05926102 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Dana Farber Cancer Institute
- Registry record
- NCT07164443 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Melanoma studies recruiting in Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Phase 1/2
- From 6 months, up to 17 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Call for Information (Investigational Site 0026)
- Registry record
- NCT02332668 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study sites
- Beth Israel Deaconess Medical Center · Massachusetts General Hospital
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Boston, MA on ClinicalTrials.gov.
Lymphoma studies recruiting in Boston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06317662 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Beth Israel Deaconess Medical Center ( Site 0161) · Dana Farber Cancer Institute ( Site 0111)
- Registry record
- NCT06890884 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Dana-Farber Cancer Institute · Tufts Medical Center
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05675410 · updated
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT07015242 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- Tufts Medical Center
- Registry record
- NCT07188558 · updated
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Phase 1/2
- From 6 months, up to 25 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Dana-Farber Cancer Institute ( Site 1013)
- Registry record
- NCT06395103 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study sites
- Beth Israel Deaconess Medical Center · Massachusetts General Hospital
- Registry record
- NCT06500273 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06124157 · updated
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- DFCI/BWH Brigham and Women's Hospital
- Registry record
- NCT06059391 · updated
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Phase 1
- Ages 18 to 75
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- Brigham and Women's Hospital
- Registry record
- NCT07020533 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Boston, MA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05372614 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Ask about studies near Boston
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections